-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the disease of peritoneal cancer is relatively unfamiliar, there are many cases of this disease in China
.
According to the industry, because the main physical manifestation of this disease is abdominal pain, many people regard this disease as appendicitis, which also causes many patients to be unable to be treated in time
.
In order to promote the development of peritoneal cancer drugs, two pharmaceutical companies have recently joined hands to launch clinical trials of drugs under research for this disease
.
On the evening of December 9, Yasheng Pharmaceutical issued an announcement announcing that Jiangsu Yasheng Pharmaceutical Development Co.
, Ltd.
, an indirect wholly-owned subsidiary of the company, and Clover Biopharmaceuticals (Hong Kong) Co.
, Limited, a wholly-owned subsidiary of Clover Biopharmaceuticals Co.
, Ltd.
, reached a joint venture.
Therapeutic cooperation agreement
.
The agreement stipulates that the two parties will jointly evaluate Shamrock Bio's recombinant human TRAIL-trimer fusion protein (SCB-313) and the SMAC mimic/inhibitor of apoptosis protein (IAP) targeted therapy small molecule antagonist ( APG-1387), the effect of combined treatment of advanced peritoneal cancer in phase 1b/2 clinical trials
.
The trial will be carried out in multiple locations in China and Australia
.
Among them, Yasheng Pharmaceutical will jointly carry out this open, multi-center phase 1b/2 clinical study with the group to evaluate the combination therapy of APG-1387 and SCB-313 in the treatment of primary or secondary (different plateau tumors).
Source) Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and efficacy of patients with peritoneal cancer
.
According to the announcement issued by Clover Biology, the signing of the cooperation agreement is beneficial for the parties to explore innovative treatment options and surgical alternatives for patients with peritoneal cancer, and is expected to target different links in the apoptosis pathway.
The synergistic benefits of combination therapy will be of great benefit to patients
.
It is understood that Clover Bio is a biopharmaceutical company in the clinical trial stage, dedicated to the development of new vaccines and biological therapies
.
The development of this cooperation has also promoted the rise of Shamrock Biology transactions.
For example, on December 10, Shamrock Biology continued to open higher in early trading.
.
As of 9:20, Shamrock Bio rose 2.
49%, quoted at 13.
98 Hong Kong dollars, with a turnover of 300,600
.
Yasheng Pharmaceuticals is an enterprise mainly dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases
.
The company has a self-constructed protein-protein interaction targeted drug design platform, and has established a pipeline of 8 class 1 small molecule new drug products that have entered the clinical development stage, including inhibiting cell apoptosis such as Bcl-2, IAP or MDM2-p53 Inhibitors of key proteins in the pathway are a new generation of inhibitors for kinase mutants that appear in cancer treatment
.
In addition to the cooperation with Shamrock Bio, Ascent Pharmaceuticals also recently announced that it has reached a clinical research cooperation with Merck.
The two parties will discuss the original MDM2-p53 inhibitor APG-115 and Merck’s PD-1 single A clinical study of anti-KEYTRUDA® (pembrolizumab) combination therapy was launched to evaluate the clinical effect of the combination in patients with advanced solid tumors
.
.
According to the industry, because the main physical manifestation of this disease is abdominal pain, many people regard this disease as appendicitis, which also causes many patients to be unable to be treated in time
.
In order to promote the development of peritoneal cancer drugs, two pharmaceutical companies have recently joined hands to launch clinical trials of drugs under research for this disease
.
On the evening of December 9, Yasheng Pharmaceutical issued an announcement announcing that Jiangsu Yasheng Pharmaceutical Development Co.
, Ltd.
, an indirect wholly-owned subsidiary of the company, and Clover Biopharmaceuticals (Hong Kong) Co.
, Limited, a wholly-owned subsidiary of Clover Biopharmaceuticals Co.
, Ltd.
, reached a joint venture.
Therapeutic cooperation agreement
.
The agreement stipulates that the two parties will jointly evaluate Shamrock Bio's recombinant human TRAIL-trimer fusion protein (SCB-313) and the SMAC mimic/inhibitor of apoptosis protein (IAP) targeted therapy small molecule antagonist ( APG-1387), the effect of combined treatment of advanced peritoneal cancer in phase 1b/2 clinical trials
.
The trial will be carried out in multiple locations in China and Australia
.
Among them, Yasheng Pharmaceutical will jointly carry out this open, multi-center phase 1b/2 clinical study with the group to evaluate the combination therapy of APG-1387 and SCB-313 in the treatment of primary or secondary (different plateau tumors).
Source) Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and efficacy of patients with peritoneal cancer
.
According to the announcement issued by Clover Biology, the signing of the cooperation agreement is beneficial for the parties to explore innovative treatment options and surgical alternatives for patients with peritoneal cancer, and is expected to target different links in the apoptosis pathway.
The synergistic benefits of combination therapy will be of great benefit to patients
.
It is understood that Clover Bio is a biopharmaceutical company in the clinical trial stage, dedicated to the development of new vaccines and biological therapies
.
The development of this cooperation has also promoted the rise of Shamrock Biology transactions.
For example, on December 10, Shamrock Biology continued to open higher in early trading.
.
As of 9:20, Shamrock Bio rose 2.
49%, quoted at 13.
98 Hong Kong dollars, with a turnover of 300,600
.
Yasheng Pharmaceuticals is an enterprise mainly dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases
.
The company has a self-constructed protein-protein interaction targeted drug design platform, and has established a pipeline of 8 class 1 small molecule new drug products that have entered the clinical development stage, including inhibiting cell apoptosis such as Bcl-2, IAP or MDM2-p53 Inhibitors of key proteins in the pathway are a new generation of inhibitors for kinase mutants that appear in cancer treatment
.
In addition to the cooperation with Shamrock Bio, Ascent Pharmaceuticals also recently announced that it has reached a clinical research cooperation with Merck.
The two parties will discuss the original MDM2-p53 inhibitor APG-115 and Merck’s PD-1 single A clinical study of anti-KEYTRUDA® (pembrolizumab) combination therapy was launched to evaluate the clinical effect of the combination in patients with advanced solid tumors
.
